Flavio Fazioli

Vasculogenic Mimicry: A Potential Therapeutic Target for Chondrosarcoma Therapy

Vincenzo Ingangi, R. Gatti, Gioconda Di Carluccio, Vincenzo Di Vaia et autres

Chondrosarcomas (ChSs) are mesenchymal chemo- and radiation-resistant tumors, representing the second most frequently diagnosed bone sarcoma after osteosarcoma and 20% of all bone sarcomas. Most of ChS patients have a good prognosis after complete surgical resection. Conversely, patients with inoperable disease, due …

it (code pays fourni par la source)

Correction: Mosca et al. Sarcoma Common MHC-I Haplotype Restricts Tumor-Specific CD8+ T Cell Response. Cancers 2022, 14, 3414

Laura Mosca, A. De Angelis, Andrea Ronchi, Annarosaria De Chiara et autres

In the original publication [...].

it (code pays fourni par la source)

Correction: Postsurgery fluids promote transition of cancer stem cell toendothelial and AKT/mTOR activity contributing to relapse of giant cell tumors of bone

Flavio Fazioli, Gianluca Colella, Roberta Miceli, Mariano Giuseppe Di Salvatore et autres

it, my (code pays fourni par la source)

Emerging Treatments Targeting the Tumor Microenvironment for Advanced Chondrosarcoma

Vincenzo Ingangi, Annarosaria De Chiara, Gerardo Ferrara, Michele Gallo et autres

Chondrosarcoma (ChS), a malignant cartilage-producing tumor, is the second most frequently diagnosed osseous sarcoma after osteosarcoma. It represents a very heterogeneous group of malignant chemo- and radiation-resistant neoplasms, accounting for approximately 20% of all bone sarcomas. The majority of ChS patients have …

it (code pays fourni par la source)

Increasing differential diagnosis between lipoma and liposarcoma through radiomics: a narrative review

Raffaele Natella, Giulia Varriano, Maria Chiara Brunese, Marcello Zappia et autres

Soft tissue sarcomas (STSs) are rare, heterogeneous, and very often asymptomatic diseases. Their diagnosis is fundamental, as is the identification of the degree of malignancy, which may be high, medium, or low. The Italian Medical Oncology Association and European Society of Medical …

it (code pays fourni par la source)

Sarcoma Common MHC-I Haplotype Restricts Tumor-Specific CD8+ T Cell Response

Laura Mosca, Alessandra De Angelis, Andrea Ronchi, Annarosaria De Chiara et autres

The major histocompatibility complex (MHC) class I expression in cancer cells has a crucial impact on the outcome of T cell-mediated cancer immunotherapy. We now determined the HLA class I allelic variants and their expression in PD-L1-deficient and positive rare sarcoma tissues. …

it (code pays fourni par la source)

Lysosome purinergic receptor P2X4 regulates neoangiogenesis induced by microvesicles from sarcoma patients

Wulf Palinski, Maria Monti, Rosa Camerlingo, Ilaria Iacobucci et autres

Abstract The tumor microenvironment modulates cancer growth. Extracellular vesicles (EVs) have been identified as key mediators of intercellular communication, but their role in tumor growth is largely unexplored. Here, we demonstrate that EVs from sarcoma patients promote neoangiogenesis via a purinergic X …

us, it (code pays fourni par la source)

Crosstalk between Macrophages and Myxoid Liposarcoma Cells Increases Spreading and Invasiveness of Tumor Cells

Michele Minopoli, Sabrina Sarno, L. Cannella, Salvatore Tafuto et autres

Myxoid liposarcoma (MLPS) is the second most common subtype of liposarcoma and has tendency to metastasize to soft tissues. To date, the mechanisms of invasion and metastasis of MLPS remain unclear, and new therapeutic strategies that improve patients' outcomes are expected. In …

it (code pays fourni par la source)

Operating procedures for electrochemotherapy in bone metastases: Results from a multicenter prospective study on 102 patients

L Campanacci, Giuseppe Bianchi, Luca Cevolani, Costantino Errani et autres

it, fr, my (code pays fourni par la source)

Is immunotherapy in the future of therapeutic management of sarcomas?

Ottavia Clemente, Alessandro Ottaiano, Giuseppe Di Lorenzo, Alessandra Bracigliano et autres

Sarcomas are rare, ubiquitous and heterogeneous tumors usually treated with surgery, chemotherapy, target therapy, and radiotherapy. However, 25-50% of patients experience local relapses and/or distant metastases after chemotherapy with an overall survival about 12-18 months. Recently, immuno-therapy has revolutionized the cancer treatments …

it (code pays fourni par la source)

Inhibiting Monocyte Recruitment to Prevent the Pro-Tumoral Activity of Tumor-Associated Macrophages in Chondrosarcoma

Michele Minopoli, Sabrina Sarno, Gioconda Di Carluccio, Rosa Azzaro et autres

Chondrosarcomas (CHS) are malignant cartilaginous neoplasms with diverse morphological features, characterized by resistance to chemo- and radiation therapies. In this study, we investigated the role of tumor-associated macrophages (TAM)s in tumor tissues from CHS patients by immunohistochemistry. Three-dimensional organotypic co-cultures were set …

it (code pays fourni par la source)

Recurrence of tumoral calcinosis: a case report.

Fabio Sandomenico, Antonio Corvino, Francesco Michele Ronza, Orlando Catalano et autres

We describe radiographic, contrast-enhanced MDCT and MRI findings with pathologic correlations of an unusual recurrence of tumoral calcinosis, also called Teutschlander disease. The disease was silent in the first decade of life, when it appeared with elbows recurring lesions, until the seventh …

my (code pays fourni par la source)